Andrew Cheng - 09 Sep 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President and CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
09 Sep 2022
Net transactions value
+$9,251
Form type
4
Filing time
13 Sep 2022, 21:13:24 UTC
Previous filing
26 May 2022
Next filing
15 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Award $9,251 +1,152 +0.37% $8.03* 310,148 30 Jun 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +87,221 $0.000000 87,221 09 Sep 2022 Common Stock 87,221 $21.10 Direct F2
transaction AKRO Stock Option (Right to Buy) Award $0 +87,221 +100% $0.000000 174,442 13 Sep 2022 Common Stock 87,221 $21.10 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired on June 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 9, 2022, the first performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option.
F3 On December 8, 2021, the Reporting Person was granted an option to purchase 261,662 shares of the Issuer's Common Stock, subject to the achievement of three specified performance milestones. On September 13, 2022, the second performance milestone was achieved, resulting in the vesting of 87,221 shares underlying such option.